Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
35 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$53.68
Price+3.69%
$1.91
1Y
Price
Market Cap
$8.921b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-39.3%
EBITDA Margin-42.8%
Net Profit Margin+205.1%
Free Cash Flow Margin-39.3%
EBITDA Margin-42.8%
Net Profit Margin+205.1%
Free Cash Flow MarginRevenue
$873.759m
-7.4%
1y CAGR+5.3%
3y CAGR+12.5%
5y CAGREarnings
-$564.780m
-48.2%
1y CAGR-18.7%
3y CAGR-23.0%
5y CAGREPS
-$3.46
-45.4%
1y CAGR-14.1%
3y CAGR-19.3%
5y CAGRBook Value
$439.737m
$2.995b
Assets$2.555b
Liabilities$2.418b
DebtDebt to Assets
80.8%
0.6x
Debt to EBITDAFree Cash Flow
-$558.875m
-74.6%
1y CAGR-32.0%
3y CAGR-27.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company